Bris­tol My­ers flunks front­line mul­ti­ple myelo­ma tri­al, turn­ing at­ten­tion to cell ther­a­py

Cel­gene and Bris­tol My­ers Squibb may have com­bined forces, but their lat­est mix of mul­ti­ple myelo­ma treat­ments don’t ap­pear to be a good match. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.